Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.
|Podcasts|August 10, 2021
Exploring 2022 Trends in Health and Hospital Drug Spending With Vizient
Vizient recently released its Summer 2021 Pharmacy Market Outlook, which projects pharmaceutical spending for 2022 based on an analysis of its members' data. On this episode of Managed Care Cast, we talk about some of the findings.
Advertisement
What’s ahead for hospitals and health systems in projected drug spending for 2022?
Vizient recently released its
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
Advertisement
Advertisement
Trending on AJMC
1
Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
Psoriasis Is Much Rarer in Indigenous Groups Worldwide
4
FDA Approves First Heart Valve to Keep Pace With Children's Growth
5